Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
Affiliation
Medical Department B ,Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology, and Diabetes ,Brandenburg Medical School ,University Hospital Ruppin-Brandenburg ,Neuruppin ,Germany
Medical Department B ,Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology, and Diabetes ,Brandenburg Medical School ,University Hospital Ruppin-Brandenburg ,Neuruppin ,Germany
Medical Department B ,Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology, and Diabetes ,Brandenburg Medical School ,University Hospital Ruppin-Brandenburg ,Neuruppin ,Germany
Medical Department B ,Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology, and Diabetes ,Brandenburg Medical School ,University Hospital Ruppin-Brandenburg ,Neuruppin ,Germany
Medical Department B ,Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology, and Diabetes ,Brandenburg Medical School ,University Hospital Ruppin-Brandenburg ,Neuruppin ,Germany
Department of Hepatology and Gastroenterology ,Charité—Universitätsmedizin Berlin ,Corporate Member of Freie Universität Berlin and Humboldt—Universität zu Berlin ,Berlin ,Germany